To access the live webcast, please log on to the Company's website at
www.cvt.com and go to the Investor Information section. Alternatively,
domestic callers may participate in the conference call by dialing
(866) 524-6241, and international callers may participate in the conference
call by dialing (706) 679-3061. Webcast and telephone replays of the
conference call will be available approximately two hours after the completion
of the call through
About CV Therapeutics
CV Therapeutics, Inc., headquartered in
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging studies in patients unable to undergo adequate exercise stress. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.
SOURCE CV Therapeutics, Inc.